[Acceptability of auto-injection of vasoactive drugs in the treatment of erectile dysfunction].
OBJECTIVE
To study the utility of the PenInject 2.25 (SHL Medical AB), an instrument for intracavernous auto-injection of vasoactive drugs.


METHODS
61 males, aged 30-70 years, with erectile dysfunction were studied. The study comprised two groups: group A consisted of 26 patients previously treated with intracavernous injections using a syringe that were started on treatment with the self-injector, and group B consisted of 35 previously untreated patients that started treatment directly with the self-injector. Different data and questions on the facility of use and acceptance of the instrument were analyzed. Data evaluation were plotted on visual analog scales of 10 cm. A score of 5 or more showed good results and less than 5 was considered unfavorable.


RESULTS
The positive aspects were facility of use, comfort, design of the self-injector, which scored higher than 7. The negative aspects were pain, fear, discomfort intensity, which scored below 4.


CONCLUSIONS
The use of the PenInject self-injector in this group of patients improved the acceptability of intracavernous therapy for erectile dysfunction in comparison to the classical syringe.
Ribé Subirà
N
N
Servicio de Andrología, Fundación Puigvert, Barcelona, España. andrologia@fundacio-puigvert.es
Vives
A
A
Jurado
C
C
Rajmil
O
O
Pomerol
J M
JM
D000368:Aged; D004867:Equipment Design; D006801:Humans; D018783:Impotence, Vasculogenic / Q000188:drug therapy*; D007267:Injections / Q000295:instrumentation; D008297:Male; D008875:Middle Aged; D012646:Self Administration; D014665:Vasodilator Agents / Q000008:administration & dosage*
D014665:Vasodilator Agents